ReviewCNS drugs2007
Duloxetine: a review of its use in the treatment of major depressive disorder.
Review in CNS drugs, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 4 syntheses or guidelines pooled it, 7 citations in OpenAlex.
- A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI.Drugs in R&D · 2017Pooled it
- Duloxetine versus other anti-depressive agents for depression.The Cochrane database of systematic reviews · 2012Pooled it
- Milnacipran versus other antidepressive agents for depression.The Cochrane database of systematic reviews · 2009Pooled it
- Pooled it
- Trial
- Short-term duloxetine administration affects neural correlates of mood-congruent memory.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2011Trial
- Dissociable effects of acute antidepressant drug administration on subjective and emotional processing measures in healthy volunteers.Psychopharmacology · 2008Trial
- Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.PharmacoEconomics · 2008Trial
- Current Opinions about the Use of Duloxetine: Results from a Survey Aimed at Psychiatrists.Brain sciences · 2023Article
- Role of FKBP5 and its genetic mutations in stress-induced psychiatric disorders: an opportunity for drug discovery.Frontiers in psychiatry · 2023Review
- Duloxetine versus 'active' placebo, placebo or no intervention for major depressive disorder; a protocol for a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis.Systematic reviews · 2021Article
- Defective Inflammatory Pathways in Never-Treated Depressed Patients Are Associated with Poor Treatment Response.Neuron · 2018Article
- Glucocorticoid receptor and FKBP5 expression is altered following exposure to chronic stress: modulation by antidepressant treatment.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013Article
- Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentary.Drugs in context · 2013Review
- Duloxetine: a review of its use in the management of major depressive disorder in older adults.Drugs & aging · 2013Review
- Suprathreshold duloxetine for treatment-resistant depression, anorexia nervosa binge-purging type, and obsessive-compulsive disorder: a case report.Innovations in clinical neuroscience · 2012Article
- Review
- Duloxetine in affective disorders: a naturalistic study on psychiatric and medical comorbidity, use in association and tolerability across different age groups.Clinical practice and epidemiology in mental health : CP & EMH · 2012Article
- Getting the balance right: Established and emerging therapies for major depressive disorders.Neuropsychiatric disease and treatment · 2010Article
- Continuation treatment of major depressive disorder: is there a case for duloxetine?Drug design, development and therapy · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Duloxetine (Cymbalta) is an orally administered, selective serotonin and noradrenaline reuptake inhibitor (SNRI) that has been approved for the treatment of major depressive disorder (MDD). Based on a considerable body of evidence, duloxetine at dosages ranging from 40 to 120 mg/day was effective in the short- and long-term treatment of MDD. Significant improvements versus placebo in core emotional symptoms as well as painful physical symptoms associated with depression, were seen in most, but not all, appropriately designed studies; results of meta-analyses suggested that improvements in these efficacy measures were apparent after 1-2 weeks' treatment with the highest recommended dosage of 60 mg once daily. Short-term (< or =15 weeks) administration of duloxetine at fixed or flexible dosages between 60 and 120 mg/day was noninferior to paroxetine 20 mg once daily, noninferior or inferior to escitalopram 10-20mg once daily, and had a similar global benefit-risk (GBR) profile to that of venlafaxine extended-release (XR) 150-225 mg/day in the treatment of MDD. Longer-term (6-8 months) treatment with duloxetine was similar in efficacy to paroxetine and escitalopram. Duloxetine is generally well tolerated, although it may be appropriate to avoid initiating treatment with the 60 mg/day dosage, as this has been associated with a higher discontinuation rate due to adverse events in some (but not all) comparative studies with escitalopram and venlafaxine XR. Definitive comparisons are awaited, although duloxetine seemingly provides a useful alternative to SSRIs and other SNRIs for the treatment of MDD. It also appears to be an attractive option for MDD patients presenting with painful physical symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.